Bank downplays importance of patent dispute and FDA notice to Novo Nordisk
Neither problems at a US Novo Nordisk factory nor Viatris’ challenge of three of Novo’s patents related to the diabetes drug Ozempic change Barclays’ view on the stock.
After a period of significant price increases in the Novo Nordisk share, investors are understandably anxious about the latest stories about quality problems at Novo’s factory in Clayton, US, and a patent dispute with the copycat company Mylan, Barclays assesses in a note.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
